|

Immune Biomarkers in Prostate Cancer Patients Treated With Brachytherapy

RECRUITINGSponsored by University of Erlangen-Nürnberg Medical School
Actively Recruiting
SponsorUniversity of Erlangen-Nürnberg Medical School
Started2025-12
Est. completion2028-07-31
Eligibility
Age18 Years+
SexMALE
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07131956

Summary

Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.

Eligibility

Age: 18 Years+Sex: MALEHealthy volunteers accepted
Inclusion Criteria Arm 1:

* Primary treatment with I-125 seeds or HDR-BT
* No previous treatment for prostate cancer
* Age ≥ 18 years

Inclusion Criteria Arm 2:

* HDR- or PDR-BT
* No radiation therapy within three months before salvage treatment
* Complete documentation available on previous treatment for prostate cancer
* No history of prostatectomy
* Age ≥ 18 years

Exclusion Criteria:

* Pre-existent auto-immune disease
* patients under bloodthinning medication
* substance abuse

Conditions5

CancerProstate Cancer (Diagnosis)Prostate Cancer Patients Treated by RadiotherapyProstate Cancer Patients Who Have Brachytherapy Seed ImplantProstate Cancer Recurrent

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.